EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Myocardial fibrosis and viability

Željka Dragila Tomašić, Lea Maršić, Anamaria Mikolčić, Lana Maričić, Kristina Selthofer Relatić, Darija Šnajder Mujkić

Biochemia medica · 15.06.2026 · 36 (2) · 214-227

DOI: 10.11613/bm.2026.020503 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemia medica, online erschienen am 15.06.2026. Verfasst von Željka Dragila Tomašić und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, University Hospital Centre Osijek, Osijek, Croatia. Hauptthemen laut MEDLINE: Coronary Angiography, Myocardium, Coronary Occlusion. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In patients with chronic total occlusion on coronary angiography, myocardial viability assessment is an essential tool in guiding treatment decisions, especially revascularization. Current non-invasive tests are often limited by the presence of myocardial fibrosis. This narrative review incorporates evidence from 76 studies and aims to provide an updated overview of non-invasive methods for myocardial viability assessment, with emphasis on the role of myocardial fibrosis. Every imaging modality provides valuable information, even though they differ in sensitivity, specificity, availability, radiation exposure, contraindications and limitations in the presence of fibrosis. Biomarkers that provide insight into different aspects of myocardial fibrosis – including collagen synthesis (procollagen type I carboxy-terminal propeptide and procollagen type III amino-terminal propeptide), as well as inflammation and fibrotic signalling (galectin-3) – may complement imaging by reflecting myocardial remodelling. However, main limitations to this approach are no standardized reference ranges and cut-off values, analytical variability and insufficient validation for clinical outcomes prediction. Despite their potential to guide personalized revascularization decisions, circulating fibrosis biomarkers currently remain experimental tools. Further large-scale prospective clinical studies that incorporate biomarkers with imaging are needed before their implementation into clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary AngiographyMyocardiumCoronary OcclusionHumansBiomarkersFibrosisChronic Disease

Stichwörter der Autor:innen

biomarkerscollagencoronary artery diseasefibrosisgalectin 3

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Emergency Medicine, University Hospital Centre Osijek, Osijek, Croatia.
  • Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
  • Department of Emergency Medicine, General Hospital Našice, Našice, Croatia.
  • Division of Cardiology, Department of Internal Medicine, University Hospital Centre Osijek, Osijek, Croatia.
  • Clinical Institute for Nuclear Medicine and Radiation Protection, University Hospital Centre Osijek, Osijek, Croatia.

Zitieren

APA

Dragila Tomašić, Ž., Maršić, L., Mikolčić, A., Maričić, L., Selthofer Relatić, K., & Šnajder Mujkić, D. (2026). Myocardial fibrosis and viability. Biochemia medica, 36(2), 214-227. https://doi.org/10.11613/bm.2026.020503

Vancouver

Dragila Tomašić Ž, Maršić L, Mikolčić A, Maričić L, Selthofer Relatić K, Šnajder Mujkić D. Myocardial fibrosis and viability. Biochemia medica. 2026;36(2):214-227. doi:10.11613/bm.2026.020503

BibTeX
@article{DragilaTomai2026,
  author = {Dragila Tomašić, Željka and Maršić, Lea and Mikolčić, Anamaria and Maričić, Lana and Selthofer Relatić, Kristina and Šnajder Mujkić, Darija},
  title = {Myocardial fibrosis and viability},
  journal = {Biochemia medica},
  year = {2026},
  volume = {36},
  number = {2},
  pages = {214--227},
  doi = {10.11613/bm.2026.020503}
}
Kostenlos starten →